Fig 2: Upregulation of NEIL2 expression could reduce the sensitivity of NSCLC cells to cisplatin. A: NEIL2 is upregulated in NSCLC cells by exogenous expression. B: Upregulation of NEIL2 expression could increase IC50 value of NSCLC cells to cisplatin. EX: exogenous; NC: negative control. *P<0.05.

Fig 3: NEIL2 gene rs8191670 polymorphism affects PFS of advanced NSCLC patients. A: The sequencing result of rs8191670 polymorphism in NEIL2 gene. B: The PFS curves of advanced NSCLC patients with different NEIL2 rs8191670 polymorphism (N=206). The median mPFS of NSCLC patients bearing “T/T”, “T/C”, and “C/C” homozygote in NEIL2 gene rs8191670 locus were 6.1m, 4.9m, and 4.5m, respectively. The difference between “T/T” and “C/C” groups was statistically significant (P = 0.01). C: The expression of NEIL2 in NSCLC with different NEIL2 rs8191670 polymorphism.

Fig 4: MiR-548a targets NEIL2 3'UTR to suppress its expression. A: Computational algorithms predicts that miR-548a might target NEIL2 3'UTR. B: MiR-548a mimic can significantly reduce the expression level of NEIL2 in both NSCLC cell lines. C: Compared with miR-Scramble, miR-548a mimic can significantly reduce the luciferase activity of pmirGLO-WT-3'UTR clone in HEK293T cells. However, neither miR-Scramble nor miR-548a mimic can affect the luciferase activity of mirGLO-MT-3'UTR clone. D: MiR-548a mimic cannot significantly reduce the luciferase activity of pmirGLO clone with SNP “C” in 3'UTR of NEIL2 gene in HEK293T cells. *P<0.05.